Skip to main content

Does Onfi cause weight gain?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Nov 7, 2024.

Official answer

by Drugs.com

Key Points

  • Weight gain is not a reported side effect with Onfi (clobazam).
  • In some studies, increased appetite was a reported side effect that occurred in 2% to 5% of 179 patients and could be responsible for weight gain in some patients.
  • Increased appetite may be a dose-related side effect with Onfi.

Learn more: Which Drugs Cause Weight Gain?

Decreased appetite was also reported with Onfi in clinical studies. Decreased appetite occurred in 7% of 59 patients receiving the highest dose of Onfi, and in 3% of 59 patients in the placebo (inactive treatment) group.

Gastrointestinal (stomach area) side effects are common with Onfi. In studies, gastrointestinal disorders occurred in at least 5% of patients and more often than the placebo-treated group.

  • Vomiting: 5% to 9% (Onfi) and 5% placebo
  • Constipation: 2% to 10% (Onfi) and 0% placebo
  • Dysphagia (swallowing difficulties): 5% (Onfi at high dose) and 0% placebo

Onfi (clobazam) belongs to the benzodiazepine class of drugs and is approved by the FDA for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. It is used in combination with other anti-epileptic drugs. It comes at the pharmacy as an oral tablet or suspension.

Related questions

Bottom Line

  • In studies, weight gain has not been reported as a side effect with Onfi (clobazam).
  • Increased appetite is a known side effect related to Onfi treatment and could result in weight gain in some patients. Higher doses may be linked to increased appetites.
  • If you have concerns about weight gain or other gastrointestinal side effects with Onfi treatment speak to your health care provider.

This is not all the information you need to know about Onfi (clobazam) for safe and effective use. Review the full Onfi information here, and discuss this information and any questions with your doctor or other health care provider.

References

Read next

Is obesity a major risk factor for Covid-19?

Obesity is a major risk factor for covid-19 and people who are obese are more likely than those who are not obese to contract Covid-19 at a younger age, develop severe Covid-19, require hospitalization, oxygen, mechanical ventilation, intubation, or admission into ICU, end up in hospital sooner, or die from Covid-19. Continue reading

Mounjaro vs Ozempic: Which is right for you?

Mounjaro and Ozempic are prescription medicines used alongside diet and exercise to help control blood sugar (glucose) levels in adults with type 2 diabetes. Ozempic is also approved to lower the risk of a major cardiovascular event (like a heart attack or stroke) in patients with type 2 diabetes, as well as to reduce the risk of worsening kidney disease and heart-related death in patients with type 2 diabetes. Mounjaro has not yet received these indications, although studies are ongoing.

In a large, 2024 retrospective study in adults with overweight or obesity and treated for type 2 diabetes, Mounjaro led to at least a 5% weight loss within one year in 81.8% of adults compared to 66.5% of those using Ozempic. Continue reading

Ozempic Side Effects to Watch For

The most common Ozempic side effects with Ozempic include stomach problems, like nausea, vomiting, diarrhea, stomach pain and constipation. These tend to be mild-to-moderate and usually clear up in a few weeks in most people. Low blood sugar (hypoglycemia) is also a common side effect (when used with certain other diabetes treatments) and it can be serious. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer